Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 785

1.

Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate.

Verhoeven MMA, Tekstra J, Welsing PMJ, Pethö-Schramm A, Borm MEA, Bruyn GAW, Bos R, Griep EN, Klaasen R, van Laar JM, Lafeber FPJG, Bijlsma JWJ, de Hair MJH, Jacobs JWG.

Rheumatology (Oxford). 2019 Dec 20. pii: kez602. doi: 10.1093/rheumatology/kez602. [Epub ahead of print]

PMID:
31859346
2.

Legal insanity and risk: An international perspective on the justification of indeterminate preventive commitment.

Bijlsma J, Kooijmans T, de Jong F, Meynen G.

Int J Law Psychiatry. 2019 Sep - Oct;66:101462. doi: 10.1016/j.ijlp.2019.101462. Epub 2019 Jul 1.

PMID:
31706396
3.

Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials.

Verhoeven MM, de Hair MJ, Tekstra J, Bijlsma JW, van Laar JM, Pethoe-Schramm A, Borm ME, Ter Borg EJ, Linn-Rasker SP, Teitsma XM, Lafeber FP, Jacobs JW, Welsing PM.

Ann Rheum Dis. 2019 Oct;78(10):1333-1338. doi: 10.1136/annrheumdis-2019-215304. Epub 2019 Jun 13.

PMID:
31196844
4.

A global perspective on the challenges and opportunities in learning about rheumatic and musculoskeletal diseases in undergraduate medical education : White paper by the World Forum on Rheumatic and Musculoskeletal Diseases (WFRMD).

Al Maini M, Al Weshahi Y, Foster HE, Chehade MJ, Gabriel SE, Saleh JA, Al Wahshi H, Bijlsma JWJ, Cutolo M, Lakhanpal S, Venkatramana M, Pineda C, Woolf AD.

Clin Rheumatol. 2019 May 24. doi: 10.1007/s10067-019-04544-y. [Epub ahead of print] Review.

PMID:
31127461
5.

Effectiveness of Remission Induction Strategies for Early Rheumatoid Arthritis: a Systematic Literature Review.

Verhoeven MMA, Welsing PMJ, Bijlsma JWJ, van Laar JM, Lafeber FPJG, Tekstra J, Jacobs JWG.

Curr Rheumatol Rep. 2019 Apr 23;21(6):24. doi: 10.1007/s11926-019-0821-1. Review.

6.

Is prediction of clinical response to methotrexate in individual rheumatoid arthritis patients possible? A systematic literature review.

Roodenrijs NMT, van der Goes MC, Welsing PMJ, Tekstra J, van Laar JM, Lafeber FPJG, Bijlsma JWJ, Jacobs JWG.

Joint Bone Spine. 2020 Jan;87(1):13-23. doi: 10.1016/j.jbspin.2019.04.002. Epub 2019 Apr 11.

PMID:
30981868
7.

Risk-Based Bioengineering Strategies for Reliable Bacterial Vaccine Production.

Kamminga T, Slagman SJ, Martins Dos Santos VAP, Bijlsma JJE, Schaap PJ.

Trends Biotechnol. 2019 Aug;37(8):805-816. doi: 10.1016/j.tibtech.2019.03.005. Epub 2019 Apr 5. Review.

8.

Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider.

Unger J, Putrik P, Buttgereit F, Aletaha D, Bianchi G, Bijlsma JWJ, Boonen A, Cikes N, Dias JM, Falzon L, Finckh A, Gossec L, Kvien TK, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Dejaco C, Ramiro S.

RMD Open. 2018 Dec 5;4(2):e000756. doi: 10.1136/rmdopen-2018-000756. eCollection 2018.

9.

EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology.

Dejaco C, Putrik P, Unger J, Aletaha D, Bianchi G, Bijlsma JW, Boonen A, Cikes N, Finckh A, Gossec L, Kvien TK, Madruga Dias J, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Ramiro S, Buttgereit F.

RMD Open. 2018 Dec 5;4(2):e000780. doi: 10.1136/rmdopen-2018-000780. eCollection 2018.

10.

International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group.

Oude Voshaar MAH, Das Gupta Z, Bijlsma JWJ, Boonen A, Chau J, Courvoisier DS, Curtis JR, Ellis B, Ernestam S, Gossec L, Hale C, Hornjeff J, Leung KYY, Lidar M, Mease P, Michaud K, Mody GM, Ndosi M, Opava CH, Pinheiro GRC, Salt M, Soriano ER, Taylor WJ, Voshaar MJH, Weel AEAM, de Wit M, Wulffraat N, van de Laar MAFJ, Vonkeman HE.

Arthritis Care Res (Hoboken). 2019 Dec;71(12):1556-1565. doi: 10.1002/acr.23799.

11.

Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology.

Teitsma XM, Yang W, Jacobs JWG, Pethö-Schramm A, Borm MEA, Harms AC, Hankemeier T, van Laar JM, Bijlsma JWJ, Lafeber FPJG.

Arthritis Res Ther. 2018 Oct 15;20(1):230. doi: 10.1186/s13075-018-1729-2.

12.

Short-term clinical worsening is a clear predictor for worsening at 2 years in established knee and hip osteoarthritis.

Mahler EAM, den Broeder AA, den Broeder N, Bijlsma JWJ, Snijders GF, van den Hoogen FHJ, van den Ende CHM.

Clin Exp Rheumatol. 2019 May-Jun;37(3):414-421. Epub 2018 Sep 17.

PMID:
30299244
13.

Cross-sectional survey of the undergraduate rheumatology curriculum in European medical schools: a EULAR School of Rheumatology initiative.

Abhishek A, Iagnocco A, Bijlsma JWJ, Doherty M, Lioté F.

RMD Open. 2018 Sep 21;4(2):e000743. doi: 10.1136/rmdopen-2018-000743. eCollection 2018.

14.

Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis.

Teitsma XM, Jacobs JWG, de Jong PHP, Hazes JMW, Weel AEAM, Welsing PMJ, Pethö-Schramm A, Borm MEA, van Laar JM, Bijlsma JWJ, Lafeber FPJG.

Ann Rheum Dis. 2019 Jan;78(1):142-144. doi: 10.1136/annrheumdis-2018-213767. Epub 2018 Aug 29. No abstract available.

PMID:
30158123
15.

RNA sequencing to predict response to TNF-α inhibitors reveals possible mechanism for nonresponse in smokers.

Cuppen BVJ, Rossato M, Fritsch-Stork RDE, Concepcion AN, Linn-Rasker SP, Bijlsma JWJ, van Laar JM, Lafeber FPJG, Radstake TR; all SRU investigators.

Expert Rev Clin Immunol. 2018 Jul;14(7):623-633. doi: 10.1080/1744666X.2018.1480937. Epub 2018 Jun 6.

PMID:
29808722
16.

Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors.

Teitsma XM, Jacobs JWG, Welsing PMJ, de Jong PHP, Hazes JMW, Weel AEAM, Pethö-Schramm A, Borm MEA, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Ann Rheum Dis. 2018 Sep;77(9):1261-1267. doi: 10.1136/annrheumdis-2018-213035. Epub 2018 May 14.

PMID:
29760159
17.

Explorative analyses of protein biomarkers in patients with early rheumatoid arthritis achieving sustained drug-free remission after treatment with tocilizumab- or methotrexate-based strategies: from transcriptomics to proteomics.

Teitsma XM, Jacobs JWG, Concepcion AN, Pethö-Schramm A, Borm MEA, van Laar JM, Bijlsma JWJ, Lafeber FPJG.

Clin Exp Rheumatol. 2018 Nov-Dec;36(6):976-983. Epub 2018 May 8.

18.

Fatigue, anxiety, depression and quality of life in kidney transplant recipients, haemodialysis patients, patients with a haematological malignancy and healthy controls.

van Sandwijk MS, Al Arashi D, van de Hare FM, van der Torren JMR, Kersten MJ, Bijlsma JA, Ten Berge IJM, Bemelman FJ.

Nephrol Dial Transplant. 2019 May 1;34(5):833-838. doi: 10.1093/ndt/gfy103.

PMID:
29726909
19.

The antibody response in the bovine mammary gland is influenced by the adjuvant and the site of subcutaneous vaccination.

Boerhout EM, Koets AP, Mols-Vorstermans TGT, Nuijten PJM, Hoeijmakers MJH, Rutten VPMG, Bijlsma JJE.

Vet Res. 2018 Mar 1;49(1):25. doi: 10.1186/s13567-018-0521-2.

20.

Disease activity and dropout in young persons with juvenile idiopathic arthritis in transition of care: a longitudinal observational study.

van Pelt PA, Dolhain RJEM, Kruize AA, Ammerlaan JJW, Hazes JW, Bijlsma JWJ, Wulffraat NM.

Clin Exp Rheumatol. 2018 Jan-Feb;36(1):163-168. Epub 2018 Jan 31.

PMID:
29461957
21.

Patient-physician collaboration in rheumatology: a necessity.

Nikiphorou E, Alunno A, Carmona L, Kouloumas M, Bijlsma J, Cutolo M.

RMD Open. 2017 Jul 18;3(1):e000499. doi: 10.1136/rmdopen-2017-000499. eCollection 2017.

22.

Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies.

Teitsma XM, Jacobs JWG, Welsing PMJ, Pethö-Schramm A, Borm MEA, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Rheumatology (Oxford). 2018 Feb 1;57(2):309-317. doi: 10.1093/rheumatology/kex386.

PMID:
29095992
23.

Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy.

Teitsma XM, Jacobs JWG, Welsing PMJ, Pethö-Schramm A, Borm MEA, Hendriks L, Denissen NHAM, van Laar JM, Lafeber FPJG, Bijlsma JWJ.

Rheumatology (Oxford). 2017 Dec 1;56(12):2179-2189. doi: 10.1093/rheumatology/kex319.

PMID:
29029185
24.

Response to eLetter: 'Discussion of methotrexate dosage' by Maguire et al.

Safy M, Jacobs JWG, Ijff ND, Bijlsma JWJ, van Laar JM, de Hair MJH; Society for Rheumatology Research Utrecht (SRU).

Ann Rheum Dis. 2018 Aug;77(8):e48. doi: 10.1136/annrheumdis-2017-212380. Epub 2017 Oct 9. No abstract available.

PMID:
28993345
25.

Patient Acceptable Symptom State in Knee Osteoarthritis Patients Succeeds Across Different Patient-reported Outcome Measures Assessing Physical Function, But Fails Across Other Dimensions and Rheumatic Diseases.

Mahler EAM, Boers N, Bijlsma JWJ, van den Hoogen FHJ, den Broeder AA, van den Ende CHM.

J Rheumatol. 2018 Jan;45(1):122-127. doi: 10.3899/jrheum.170181. Epub 2017 Aug 15.

PMID:
28811352
26.

Will we ever have better glucocorticoids?

Buttgereit F, Bijlsma JWJ, Strehl C.

Clin Immunol. 2018 Jan;186:64-66. doi: 10.1016/j.clim.2017.07.023. Epub 2017 Jul 27.

PMID:
28757452
27.

Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy.

Teitsma XM, Jacobs JWG, Mokry M, Borm MEA, Pethö-Schramm A, van Laar JM, Bijlsma JWJ, Lafeber FPJ.

Arthritis Res Ther. 2017 Jul 20;19(1):170. doi: 10.1186/s13075-017-1378-x.

28.

Proteomics to predict the response to tumour necrosis factor-α inhibitors in rheumatoid arthritis using a supervised cluster-analysis based protein score.

Cuppen B, Fritsch-Stork R, Eekhout I, de Jager W, Marijnissen AC, Bijlsma J, Custers M, van Laar JM, Lafeber F, Welsing P; all Society for Rheumatology Research Utrecht (SRU) investigators.

Scand J Rheumatol. 2018 Jan;47(1):12-21. doi: 10.1080/03009742.2017.1309061. Epub 2017 Jun 26.

PMID:
28650254
29.

A disconnect between disease activity and functional ability already in patients with early rheumatoid arthritis, depending on large joint involvement.

Rubbert-Roth A, Jacobs JWG, Bijlsma JWJ, Welsing PMJ.

Ann Rheum Dis. 2018 Jul;77(7):1085-1086. doi: 10.1136/annrheumdis-2017-211485. Epub 2017 Jun 23. No abstract available.

PMID:
28646081
30.

Managing rheumatic and musculoskeletal diseases - past, present and future.

Burmester GR, Bijlsma JWJ, Cutolo M, McInnes IB.

Nat Rev Rheumatol. 2017 Jul;13(7):443-448. doi: 10.1038/nrrheum.2017.95. Epub 2017 Jun 15. Review.

PMID:
28615732
31.

Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial.

Bouman CA, van Herwaarden N, van den Hoogen FH, Fransen J, van Vollenhoven RF, Bijlsma JW, Maas AV, den Broeder AA.

Ann Rheum Dis. 2017 Oct;76(10):1716-1722. doi: 10.1136/annrheumdis-2017-211169. Epub 2017 Jun 12.

PMID:
28606961
32.

Metabolic modeling of energy balances in Mycoplasma hyopneumoniae shows that pyruvate addition increases growth rate.

Kamminga T, Slagman SJ, Bijlsma JJE, Martins Dos Santos VAP, Suarez-Diez M, Schaap PJ.

Biotechnol Bioeng. 2017 Oct;114(10):2339-2347. doi: 10.1002/bit.26347. Epub 2017 Jul 27.

33.

Glucocorticoids in rheumatoid arthritis: the picture is shaping up.

Buttgereit F, Bijlsma JW.

Ann Rheum Dis. 2017 Nov;76(11):1785-1787. doi: 10.1136/annrheumdis-2017-211187. Epub 2017 May 4. No abstract available.

PMID:
28473424
34.

Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial.

Safy M, Jacobs J, IJff ND, Bijlsma J, van Laar JM, de Hair M; Society for Rheumatology Research Utrecht (SRU).

Ann Rheum Dis. 2017 Aug;76(8):1432-1435. doi: 10.1136/annrheumdis-2016-210647. Epub 2017 Apr 27.

PMID:
28450312
35.

EULAR recommendations for the use of imaging in the clinical management of peripheral joint osteoarthritis.

Sakellariou G, Conaghan PG, Zhang W, Bijlsma JWJ, Boyesen P, D'Agostino MA, Doherty M, Fodor D, Kloppenburg M, Miese F, Naredo E, Porcheret M, Iagnocco A.

Ann Rheum Dis. 2017 Sep;76(9):1484-1494. doi: 10.1136/annrheumdis-2016-210815. Epub 2017 Apr 7.

36.

A multi-parameter response prediction model for rituximab in rheumatoid arthritis.

de Jong TD, Sellam J, Agca R, Vosslamber S, Witte BI, Tsang-A-Sjoe M, Mantel E, Bijlsma JW, Voskuyl AE, Nurmohamed MT, Verweij CL, Mariette X.

Joint Bone Spine. 2018 Mar;85(2):219-226. doi: 10.1016/j.jbspin.2017.02.015. Epub 2017 Mar 28.

PMID:
28363827
37.

The most important needs and preferences of patients for support from health care professionals: A reflective practice on (transitional) care for young adults with Juvenile Idiopathic Arthritis.

Ammerlaan JW, van Os-Medendorp H, de Boer-Nijhof NC, Prakken B, Bijlsma JWJ, Kruize AA.

Patient Educ Couns. 2017 Oct;100(10):1961-1964. doi: 10.1016/j.pec.2017.03.018. Epub 2017 Mar 12.

PMID:
28363359
38.

Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.

Chatzidionysiou K, Emamikia S, Nam J, Ramiro S, Smolen J, van der Heijde D, Dougados M, Bijlsma J, Burmester G, Scholte M, van Vollenhoven R, Landewé R.

Ann Rheum Dis. 2017 Jun;76(6):1102-1107. doi: 10.1136/annrheumdis-2016-210711. Epub 2017 Mar 29. Review.

PMID:
28356243
39.

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.

Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, Bijlsma JW, Burmester GR, Scholte-Voshaar M, Falzon L, Landewé RBM.

Ann Rheum Dis. 2017 Jun;76(6):1101-1136. doi: 10.1136/annrheumdis-2016-210708. Epub 2017 Mar 15. Review.

PMID:
28298374
40.

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.

Nam JL, Takase-Minegishi K, Ramiro S, Chatzidionysiou K, Smolen JS, van der Heijde D, Bijlsma JW, Burmester GR, Dougados M, Scholte-Voshaar M, van Vollenhoven R, Landewé R.

Ann Rheum Dis. 2017 Jun;76(6):1113-1136. doi: 10.1136/annrheumdis-2016-210713. Epub 2017 Mar 10. Review.

PMID:
28283512
41.

How should worsening in osteoarthritis be defined? Development and initial validation of preliminary criteria for clinical worsening in knee and hip osteoarthritis.

Mahler E, den Broeder AA, Woodworth TG, Busch V, van den Hoogen FH, Bijlsma J, van den Ende C.

Scand J Rheumatol. 2017 Sep;46(5):396-406. doi: 10.1080/03009742.2016.1235226. Epub 2017 Feb 7.

PMID:
28276959
42.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Review.

43.

Persistence of Functional Protein Domains in Mycoplasma Species and their Role in Host Specificity and Synthetic Minimal Life.

Kamminga T, Koehorst JJ, Vermeij P, Slagman SJ, Martins Dos Santos VA, Bijlsma JJ, Schaap PJ.

Front Cell Infect Microbiol. 2017 Feb 7;7:31. doi: 10.3389/fcimb.2017.00031. eCollection 2017.

44.

Polymorphisms in the multidrug-resistance 1 gene related to glucocorticoid response in rheumatoid arthritis treatment.

Cuppen BV, Pardali K, Kraan MC, Marijnissen AC, Yrlid L, Olsson M, Bijlsma JW, Lafeber FP, Fritsch-Stork RD.

Rheumatol Int. 2017 Apr;37(4):531-536. doi: 10.1007/s00296-017-3653-1. Epub 2017 Jan 28.

45.

Quantifying cutaneous adverse effects of systemic glucocorticoids in patients with rheumatoid arthritis: a cross-sectional cohort study.

Amann J, Wessels AM, Breitenfeldt F, Huscher D, Bijlsma JWJ, Jacobs JWG, Buttgereit F.

Clin Exp Rheumatol. 2017 May-Jun;35(3):471-476. Epub 2017 Jan 15.

PMID:
28094753
46.

Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis.

Strehl C, van der Goes MC, Bijlsma JW, Jacobs JW, Buttgereit F.

Expert Opin Investig Drugs. 2017 Feb;26(2):187-195. doi: 10.1080/13543784.2017.1276562. Epub 2017 Jan 3. Review.

PMID:
28043173
47.

"Official View" on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements.

Palmowski Y, Buttgereit T, Dejaco C, Bijlsma JW, Matteson EL, Voshaar M, Boers M, Buttgereit F.

Arthritis Care Res (Hoboken). 2017 Aug;69(8):1134-1141. doi: 10.1002/acr.23185. Epub 2017 Jul 10. Review. Erratum in: Arthritis Care Res (Hoboken). 2018 Jan;70(1):144.

48.

Erratum to: Rheumatology training experience across Europe: analysis of core competences.

Sivera F, Ramiro S, Cikes N, Cutolo M, Dougados M, Gossec L, Kvien TK, Lundberg IE, Mandl P, Moorthy A, Panchal S, da Silva JA, Bijlsma JW; Working Group on Training in Rheumatology across Europe.

Arthritis Res Ther. 2016 Dec 19;18(1):300. No abstract available.

49.

Authors' reply.

Mahler E, Cuperus N, Bijlsma J, Vliet Vlieland T, van den Hoogen F, den Broeder AA, van den Ende CH.

Scand J Rheumatol. 2017 Mar;46(2):169-170. doi: 10.1080/03009742.2016.1238961. Epub 2016 Dec 13. No abstract available.

PMID:
27957869
50.

Responsiveness of four patient-reported outcome measures to assess physical function in patients with knee osteoarthritis.

Mahler E, Cuperus N, Bijlsma J, Vliet Vlieland T, van den Hoogen F, den Broeder AA, van den Ende CH.

Scand J Rheumatol. 2016 Nov;45(6):518-527. Epub 2016 Apr 7.

PMID:
27053134

Supplemental Content

Loading ...
Support Center